• Q4 revenue increased by 9% to $1.5 billion; up 8% on a constant currency basis
• Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95
• Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026

Resmed Inc. announced strong results for its fourth quarter of fiscal year 2026, ending June 30, 2026. The company reported a 9% increase in revenue to $1.5 billion, with an 8% increase on a constant currency basis. GAAP diluted earnings per share (EPS) rose 2% to $2.64, while non-GAAP diluted EPS increased 16% to $2.95. Resmed also returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, a more than 70% increase from the previous year. The company's full-year 2026 revenue increased by 10% to $5.7 billion, with GAAP gross margin up 170 basis points to 61.1% and non-GAAP gross margin up 240 basis points to 62.4%. Resmed expects to return more than $1.85 billion to shareholders through share repurchases and dividends during fiscal year 2027, with a 10% increase in the quarterly dividend to $0.66 per share.

Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027

As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers.